Pieter F Van Der Meer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3397942/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of blood transfusion product pathogen reduction treatments: A review of methods, current applications and demands. Transfusion and Apheresis Science, 2015, 52, 19-34.	0.5	99
2	<i>In vitro</i> comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an <i>in vitro</i> rating system. Vox Sanguinis, 2010, 98, 517-524.	0.7	75
3	Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood, 2018, 132, 223-231.	0.6	71
4	Storage of platelets in additive solution for up to 12 days with maintenance of good in-vitro quality. Transfusion, 2004, 44, 1204-1211.	0.8	67
5	Commercially available blood storage containers. Vox Sanguinis, 2014, 106, 1-13.	0.7	58
6	Platelet Additive Solutions: A Review of the Latest Developments and Their Clinical Implications. Transfusion Medicine and Hemotherapy, 2018, 45, 98-102.	0.7	56
7	PAS or plasma for storage of platelets? A concise review. Transfusion Medicine, 2016, 26, 339-342.	0.5	52
8	Influence of pH on stored human platelets. Transfusion, 2007, 47, 1889-1895.	0.8	48
9	Platelet preservation: Agitation and containers. Transfusion and Apheresis Science, 2011, 44, 297-304.	0.5	47
10	Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion, 2014, 54, 2292-2300.	0.8	46
11	Platelet concentrates, from whole blood or collected by apheresis?. Transfusion and Apheresis Science, 2013, 48, 129-131.	0.5	45
12	Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study. Transfusion, 2011, 51, 50S-57S.	0.8	43
13	Flow cytometric assessment of agonistâ€induced <scp>P</scp> â€selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion, 2013, 53, 1780-1787.	0.8	37
14	Evaluation of overnight hold of whole blood at room temperature before component processing: effect of red blood cell (RBC) additive solutions on in vitro RBC measures. Transfusion, 2011, 51, 15S-24S.	0.8	35
15	Evaluation of the role of the <scp>GPI</scp> bâ€ <scp>IX</scp> â€V receptor complex in development of the platelet storage lesion. Vox Sanguinis, 2016, 111, 247-256.	0.7	33
16	Interruption of agitation of platelet concentrates: effects on in vitro parameters. Vox Sanguinis, 2005, 88, 227-234.	0.7	32
17	Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?. Transfusion, 2015, 55, 1900-1908.	0.8	32
18	The effect of whole-blood storage time on the number of white cells and platelets in whole blood and in white cell-reduced red cells. Transfusion, 2006, 46, 589-594.	0.8	31

PIETER F VAN DER MEER

#	Article	IF	CITATIONS
19	Preparation of Leukodepleted Platelet Concentrates from Pooled Buffy Coats: Prestorage Filtration with AutostoptmBC. Vox Sanguinis, 1999, 76, 231-236.	0.7	30
20	A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology. Platelets, 2019, 30, 368-379.	1.1	28
21	Prevention of red cell storage lesion: a comparison of five different additive solutions. Blood Transfusion, 2017, 15, 456-462.	0.3	28
22	Automated Separation of Whole Blood in Top and Bottom Bags into Components Using the Compomat G4. Vox Sanguinis, 1999, 76, 90-99.	0.7	27
23	Overnight storage of whole blood: a comparison of two designs of butane-1,4-diol cooling plates. Transfusion, 2007, 47, 2038-2043.	0.8	27
24	Platelet concentrates from fresh or overnightâ€stored blood, an international study. Transfusion, 2011, 51, 38S-44S.	0.8	27
25	Serum eye drops: a survey of international production methods. Vox Sanguinis, 2017, 112, 310-317.	0.7	27
26	The role of pathogenâ€reduced platelet transfusions on HLA alloimmunization in hematoâ€oncological patients. Transfusion, 2019, 59, 470-481.	0.8	27
27	Determination of thromboelastographic responsiveness in stored singleâ€donor platelet concentrates. Transfusion, 2014, 54, 1610-1618.	0.8	25
28	Gamma irradiation does not affect 7-day storage of platelet concentrates. Vox Sanguinis, 2005, 89, 97-99.	0.7	22
29	In vivo tracking of transfused platelets for recovery and survival studies: An appraisal of labeling methods. Transfusion and Apheresis Science, 2010, 42, 53-61.	0.5	22
30	Evaluation of the overnight hold of whole blood at room temperature, before component processing: platelets (PLTs) from PLT-rich plasma. Transfusion, 2011, 51, 45S-49S.	0.8	22
31	A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open, 2016, 6, e010156.	0.8	22
32	Transfusion reactions after transfusion of platelets stored in PASâ€B, PASâ€C, or plasma: a nationwide comparison. Transfusion, 2018, 58, 1021-1027.	0.8	22
33	Platelet storage performance is consistent by donor: a pilot study comparing "good―and "poor― storing platelets. Transfusion, 2017, 57, 2373-2380.	0.8	21
34	Platelet additive solutions: A future perspective. Transfusion Clinique Et Biologique, 2007, 14, 522-525.	0.2	20
35	Vox Sanguinis International Forum on platelet cryopreservation. Vox Sanguinis, 2017, 112, e69-e85.	0.7	20
36	Effect of increased agitation speed on pathogen inactivation efficacy and <i>in vitro</i> quality in UVCâ€treated platelet concentrates. Vox Sanguinis, 2016, 111, 127-134.	0.7	19

PIETER F VAN DER MEER

#	Article	IF	CITATIONS
37	Vox Sanguinis International Forum on platelet cryopreservation: Summary. Vox Sanguinis, 2017, 112, 684-688.	0.7	17
38	Allogeneic and autologous serum eye drops: a pilot doubleâ€blind randomized crossover trial. Acta Ophthalmologica, 2021, 99, 837-842.	0.6	17
39	The effect of interruption of agitation on in vitro measures of platelet concentrates in additive solution. Transfusion, 2007, 47, 955-959.	0.8	16
40	Autologous and allogeneic serum eye drops. The Dutch perspective. Transfusion and Apheresis Science, 2015, 53, 99-100.	0.5	16
41	Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion. Frontiers in Immunology, 2018, 9, 1251.	2.2	16
42	Volumeâ€reduced platelet concentrates: optimization of production and storage conditions. Transfusion, 2012, 52, 819-827.	0.8	14
43	The observation of bleeding complications in haematoâ€oncological patients: stringent watching, relevant reporting. Transfusion Medicine, 2012, 22, 426-431.	0.5	13
44	Comparison of haemostatic function of <scp>PAS</scp> –platelets vs. plasma–platelets in reconstituted whole blood using impedance aggregometry and thromboelastography. Vox Sanguinis, 2017, 112, 549-556.	0.7	12
45	Platelet storage properties are associated with donor age:inÂvitroquality of platelets from young donors and older donors with and without Type 2 diabetes. Vox Sanguinis, 2018, 114, 129-136.	0.7	12
46	The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo. Transfusion, 2019, 59, 697-706.	0.8	12
47	Comparison of various dimethylsulphoxide-containing solutions for cryopreservation of leucoreduced platelet concentrates. Vox Sanguinis, 2003, 85, 276-282.	0.7	11
48	Preparation and storage of white blood cell-reduced split apheresis platelet concentrates for pediatric use. Transfusion, 2005, 45, 223-227.	0.8	11
49	Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review. Vox Sanguinis, 2019, 114, 643-657.	0.7	11
50	Sterilization method of platelet storage containers affects in vitro parameters. Vox Sanguinis, 2007, 92, 32-36.	0.7	10
51	Counting platelets in platelet concentrates on hematology analyzers: a multicenter comparative study. Transfusion, 2009, 49, 81-90.	0.8	10
52	Experiences with semiâ€routine production of riboflavin and <scp>UV</scp> â€B pathogenâ€inactivated platelet concentrates in three blood centres. Vox Sanguinis, 2017, 112, 9-17.	0.7	10
53	A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion, 2020, 60, 1267-1277.	0.8	10
54	Multicenter evaluation of two flow cytometric methods for counting low levels of white blood cells. Transfusion, 2004, 44, 1319-1324.	0.8	9

PIETER F VAN DER MEER

#	Article	IF	CITATIONS
55	Active cooling of whole blood to room temperature improves blood component quality. Transfusion, 2011, 51, 357-362.	0.8	9
56	Apheresis versus wholeâ€bloodâ€derived platelets: pros and cons. ISBT Science Series, 2012, 7, 112-116.	1.1	9
57	Effect of storage of platelet concentrates in PASâ€B, PASâ€C, or plasma on transfusion reactions. Transfusion, 2019, 59, 3140-3145.	0.8	9
58	A flow cytometric method for platelet counting in platelet concentrates. Transfusion, 2012, 52, 173-180.	0.8	8
59	Alternatives in blood operations when choosing nonâ€ <scp>DEHP</scp> bags. Vox Sanguinis, 2017, 112, 183-184.	0.7	8
60	The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study. British Journal of Haematology, 2020, 189, 171-181.	1.2	8
61	Quality of Platelets in Stored Whole Blood. Transfusion Medicine Reviews, 2020, 34, 234-241.	0.9	7
62	Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy. Transfusion, 2021, 61, 286-293.	0.8	6
63	Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion. Transfusion, 2020, 60, 1604-1611.	0.8	5
64	An evaluation of automated blood collection mixers. Vox Sanguinis, 2006, 91, 275-277.	0.7	4
65	The effect of plastic overwraps on storage measures of red cell concentrates. Vox Sanguinis, 2007, 93, 176-178.	0.7	4
66	Measuring clinical bleeding using a standardized daily report form and a computer algorithm for adjudication of WHO bleeding grades. Vox Sanguinis, 2013, 105, 144-149.	0.7	4
67	Comparison of two sterile connection devices and the effect of sterile connections on blood component quality. Transfusion, 2006, 46, 418-423.	0.8	3
68	Increase of blood donation speed by optimizing the needle- to-tubing connection: an application of donation software. Vox Sanguinis, 2009, 97, 21-25.	0.7	3
69	Effect of solvent/detergentâ€ŧreated pooled plasma on fibrinolysis in reconstituted whole blood. Transfusion, 2017, 57, 2381-2389.	0.8	3
70	Hemostatic Efficacy of Pathogen-Inactivated Buffy Coat-Derived Platelet Concentrates in Hemato-Oncological Patients: Outcomes of the Prepares Trial. Blood, 2017, 130, 704-704.	0.6	3
71	Adverse effects of 'old' versus 'young' blood: also true for platelet concentrates?. Clinical Laboratory, 2011, 57, 260-2.	0.2	3
72	The history of buffy coat platelet concentrates: The Dutch story. Vox Sanguinis, 2022, 117, 913-919.	0.7	3

#	Article	IF	CITATIONS
73	Processing and storage of blood components: strategies to improve patient safety. International Journal of Clinical Transfusion Medicine, 2015, , 55.	0.8	1
74	Platelets from donors who use non-steroidal anti-inflammatory drugs are functional when stored under blood bank conditions. ISBT Science Series, 2018, 13, 432-439.	1.1	1
75	Obstacles to rational clinical transfusion practices in the developing world. ISBT Science Series, 2016, 11, 3-6.	1.1	0